Analysts’ recommendations and target price

Wall Street analysts expect a potential upside of 14.17% for Vertex Pharmaceuticals (VRTX) based on the stock’s closing price on March 21.

In 2019, analysts have revised the company’s target price upward twice so far, from $202.52 in January to $207.53 in February and then to $208.42 in March. The current consensus analyst recommendation for the stock is a “buy.”

Analysts Have Raised Their Target Price for VRTX in March

Of the 24 analysts covering Vertex Pharmaceuticals, seven have given it “strong buys,” 11 have given it “buys,” and six have given it “holds.” The highest target price estimate for the company is $234, and the lowest is $170.

On March 21, Vertex Pharmaceuticals closed at $182.56, 1.43% higher than its previous closing price, 26.72% higher than its 52-week low of $144.07, and 6.77% lower than its 52-week high of $195.81. The company’s market cap is $46.53 billion.

Based on its closing price on March 21, Vertex Pharmaceuticals has reported returns of -1.91% in the last week, -2.81% in the last month, and 11.71% in the last quarter. The company has reported returns of 3.07% in the last half year, 6.47% in the last year, and 10.17% year-to-date.

Revenue and EPS estimates

In its fourth quarter, Vertex Pharmaceuticals reported revenue of $870.11 million, a YoY (year-over-year) rise of 33.53% and $51.82 million higher than the consensus estimate. The company reported non-GAAP (generally accepted accounting principles) EPS of $1.30, a YoY rise of 113.11% and $0.24 higher than analysts’ consensus estimate.

Analysts expect Vertex Pharmaceuticals’ revenue to see YoY rises of 33.01% to $849.76 million in the first quarter, 17.62% to $883.58 million in the second quarter, 14.73% to $899.33 million in the third quarter, and 6.73% to $927.97 million in the fourth quarter of 2019. Analysts also expect Vertex’s non-GAAP EPS to see YoY changes of 27.89% to $0.97 in the first quarter, 7.09% to $1.01 in the second quarter, -6.09% to $1.02 in the third quarter, and -18.38% to $1.06 in the fourth quarter.

Analysts expect Vertex Pharmaceuticals’ revenue to see YoY rises of 16.95% to $3.56 billion in 2019, 26.77% to $4.51 billion in 2020, and 21.78% to $5.49 billion in 2021. Analysts also expect Vertex Pharmaceuticals’ non-GAAP EPS to see YoY rises of 0.26% to $4.09 in 2019, 54.01% to $6.30 in 2020, and 45.30% to $9.15 in 2021.

Next, we’ll discuss analysts’ recommendations and projections for BioMarin Pharmaceutical. 

Latest articles

HEXO reported its third-quarter earnings on June 12. The company reported revenues of $13.0 million, which fell short of analysts’ estimate.

The Hot Chips 31 Symposium started this week. Artificial intelligence was the hot topic among participants Intel, NVIDIA, and Advanced Micro Devices.

Today, Slack (WORK) opened 4.5% higher after MKM Partners analyst Rohit Kulkarni gave Slack stock a "buy" rating with a target price of $40.

Today, Aphria announced a deal with ParcelPal to deliver medical cannabis to patients. Also, Cole Cacciavillani's son has won a cannabis store license.

Today, IHS Markit released the US manufacturing PMI (purchasing managers’ index) data for August. The manufacturing PMI hit 49.9, down from 50.4 in July.

On May 1, smokable hemp will be banned in North Carolina. The state passed the North Carolina Farm Act, removing smokable hemp from its permissible list.